目的: 探究清肾灌肠方治疗对慢性肾病患者的疗效及对血清肌酐（serum creatine,SCr）和尿素氮（blood urea nitrogen,BUN）水平的影响。方法: 选择2021年1月—2023年9月医院收治的94例慢性肾病患者进行回顾性分析,根据治疗方法的不同将患者分为对照组（n=46）与观察组（n=48）,对照组采用常规西药对症治疗,观察组在对照组基础上采用清肾灌肠方治疗,比较两组患者疗效、SCr及BUN水平及不良反应。结果: 两组治疗有效率比较,观察组为87.50%（42/48）显著高于对照组的69.57%（32/46）;两组治疗后肾功能指标SCr、BUN水平均较治疗前显著降低,但两组治疗后SCr、BUN水平比较未见显著性差异;两组治疗期间不良反应发生情况比较未见显著差异。结论: 清肾灌肠方治疗慢性肾病患者可显著提升疗效,改善患者肾功能且不良反应发生率低,值得临床推广应用。
Abstract
Objective To explore the therapeutic effect of Qingshen Guanchang Formula on patients with chronic kidney disease, and the influence on renal function. Methods A total of 94 patients with chronic kidney disease admitted to the hospital from January 2021 to September 2023 were reviewed. According to different treatment methods, the patients were assigned to the control group (n=46) and the observation group (n=48). The former received conventional symptomatic Western medicine treatment, and the latter was treated with Qingshen Guanchang Formula on the above basis. Therapeutic effects, serum creatinine (SCr) and blood urea nitrogen (BUN) levels, and adverse reactions were compared between the two groups. Results The response rate was 87.50% (42/48) in the observation group and 69.57% (32/46) in the control group, and the former was much higher. After treatment, the levels of SCr and BUN in the observation group were significantly lower than those before treatment. There was no significant difference in the levels of SCr and BUN between the two groups after treatment. The incidence rates of adverse reactions in the two groups were comparable. Conclusion Applying Qingshen Guanchang Formula to treat patients with chronic kidney disease can significantly improve the renal function of patients and has a low incidence of adverse reactions.
关键词
慢性肾病 /
清肾灌肠方 /
肌酐 /
尿素氮
Key words
chronic kidney disease /
Qingshen Guanchang formula /
creatinine /
urea nitrogen
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al.Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288.
[2] 张英杰, 王秉新, 朱剑南, 等. 益肾健脾化瘀汤联合缬沙坦治疗慢性肾病临床研究[J]. 新中医, 2023, 55(3): 87-90.
[3] 陈晓燕, 赵翠萍, 任军华, 等. 慢性肾脏病 (3b-5期) 非透析患者择时中药保留灌肠的临床研究[J]. 中国中西医结合肾病杂志, 2022, 23(7): 628-631.
[4] 吴智鹏, 孙梦洁, 王东, 等. 中药保留灌肠治疗慢性肾功能衰竭临床研究[J]. 安徽中医药大学学报, 2021, 40(2): 40-44.
[5] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南 (2022年版)[J]. 中华肾脏病杂志, 2022, 38(5): 453-464.
[6] 商洪才, 王保和, 张伯礼. 中药新药证候及疗效评价[J]. 中药新药与临床药理, 2004(05): 365-368.
[7] 王娟, 袁毅, 茹雪, 等. 中药保留灌肠结合辨证施护对慢性肾功能衰竭患者肾功能、炎症反应及液体摄入依从性的影响[J]. 西部中医药, 2023, 36(6): 117-121.
[8] NAST CC.Chronic kidney disease with unknown cause across the global spectrum[J]. Cur Opin Nephrol Hyperten, 2023, 32(3): 223-231.
[9] 朱清, 高勇. 外周血RBP与β2M联合检测对 2~4 期慢性肾脏病并发急性肾损伤的预警价值[J]. 中南医学科学杂志, 2023, 51(2): 281-284.
[10] 丁秀, 王小琴. 基于网络药理学探讨膜肾协定方治疗特发性膜性肾病的机制[J]. 中南医学科学杂志, 2023, 51(5): 645-649, 702.
[11] 胡天祥, 卢家言, 曾露, 等. 名老中医杨霓芝教授辨治慢性肾脏病学术思想概述[J]. 中国中西医结合肾病杂志, 2022, 23(8): 662-664.
[12] 郑荣林, 陈惠琴, 陈怀. 祛风燥湿通络方治疗对3~4期慢性肾病湿热瘀滞证患者中医症候积分、氧化应激及钙磷代谢的影响[J]. 四川中医, 2022, 40(4): 117-120.
[13] 谭睿陟, 邹远霞, 刘鹏, 等. 柴黄益肾颗粒抑制巨噬细胞Mincle改善小鼠慢性肾病模型肾纤维化[J]. 中药新药与临床药理, 2023, 34(12): 1658-1667.
[14] 任桐, 王旭燕, 王家兴, 等. 黄文政教授治疗慢性肾病临证经验举隅[J]. 天津中医药, 2021, 38(7): 843-847.
[15] 陈冠廷, 任珂, 王剑锋. 基于17948篇中英文文献分析近20年中医药治疗慢性肾脏病研究热点与趋势[J]. 北京中医药大学学报, 2023, 46(6): 879-888.
[16] 文娟, 周思举. 中药保留灌肠联合胃管内灌注并持续胃肠减压对胰腺炎患者的临床疗效[J]. 中国现代医学杂志, 2021, 31(11): 81-85.
[17] 葛旭, 王国兴. 生大黄保留灌肠联合乌司他丁对脓毒症合并MODS患者免疫内稳态及炎症水平的影响[J]. 医学综述, 2022, 28(9): 1795-1800.
[18] 舒发明, 黄英, 陈玮钰, 等. 大黄煎剂保留灌肠治疗慢性乙型肝炎重症化患者的临床疗效及安全性观察[J]. 世界中西医结合杂志, 2023, 18(6): 1186-1190.
[19] 赵令富, 周恩超. 周恩超教授治疗慢性肾脏病常用药组探析[J]. 中国医药导报, 2023, 20(6): 128-131.
[20] 水光兴, 殷勋, 桑栋, 等. 大黄附子汤保护慢性肾脏病患者线粒体功能的临床随机对照研究[J]. 中国中西医结合肾病杂志, 2018, 19(1): 31-33.
[21] 董怡, 马静, 余楠楠, 等. 大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J]. 陕西中医, 2021, 42(7): 910-913.
[22] 刘毓, 刘鹏, 韩晶雪, 等. 基于网络药理学大黄治疗慢性肾脏病机制研究[J]. 中华中医药学刊, 2021, 39(02): 32-36+262-264.
基金
安徽省重点研究与开发计划项目：清肾颗粒与慢性肾脏病3-4期湿热证患者肾脏结局和安全性：一项基于真实世界的多中心、前瞻性队列研究（编号：202104j07020014）
PDF(1638 KB)
